Popular on PrZen
- Benjamin Hey! aka "The Captain" is set to release a music video for the anti-gun violence song, "Ra-tat-tat-tat." - 206
- CHRIS JASPER "Raises The Bar" with the June Release of his New Music! - 199
- Sunber Summer 2022 New Arrivals Release
- Women in Film Dallas Accepting Submissions for 21st Annual Topaz Film Festival
- Custom House Juneteenth Museum: Where the digital and physical join to deliver a unique experience
- Master P And Trick Daddy Headline The 25th Anniversary "No Limit Reunion Tour" Coming To Miami
- Terrorism is again on the rise warnings in new TERROR STRIKES book release
- What Is an Endodontist? Do I Need A Root Canal?
- SEE Company Inc. Introduces New Brand Ambassador, Ericka Dunlap at WBENC National Conference
- Genesis Homes is ready to take over the Cape Coral real estate market in South Florida
Similar on PrZen
- iTech offers 60-days free trial on expEDIum Medical Billing® product
- CPC Scientific Announces New California Peptide API Manufacturing Facility
- Calgary-based Orthodontics Provider Opens New Location
- Console & Associates: The Passing of the Camp Lejeune Act Puts Justice Within Reach
- Console & Associates, P.C. Explores Legal Options for Camp Lejeune Veterans and Families
- DocVilla launches Appointment Reminder Call feature for Medical Practices
- Perth skin cancer patients undergo first treatments with OncoBeta's Rhenium-SCT as part of the EPIC-Skin study
- Nutrition and Wellness Expert, Chaitra Dalton Bryant Joins the Board of the National Minority Health Association to Reduce Health Inequities
- Arkansas Medical, Dental, and Pharmaceutical Association, Inc. (AMDPA) Announces New President in First In-Person Scientific Session in Three Years
AbbVie Signs Cosmetic Compound Licensing Deal With Sirona Biochem
PrZen/33462602
VANCOUVER, British Columbia - PrZen -- Allergan Aesthetics, a subsidiary of AbbVie Inc., a global biopharmaceutical company, has signed a licensing deal with Sirona Biochem (TSX-V: SBM). The deal is for the use of Sirona's patented library of compounds, including its breakthrough dark spot corrector molecule known as TFC-1067. AbbVie plans to commercialize and market the ingredient and add it to its growing aesthetics and cosmetics portfolio.
The global exclusive licensing agreement includes up-front payments from AbbVie to Sirona Biochem. It also includes milestone payments and royalty payments for sales generated from commercial products using Sirona's patents. AbbVie and Sirona are expected to sign a separate definitive supply agreement, which will see the latter become a major supplier of the patented compounds.
AbbVie, through its subsidiary Allergan Aesthetics, controls a large portion of the global aesthetics market. The company, one of the top five pharmaceutical companies in the world based on revenue, plans to capitalize on Sirona Biochem's TFC-1067 compound, which is expected to replace hydroquinone as the next gold standard for creating an even skin tone.
The deal is part of Abbie's ongoing mission to discover and deliver new and innovative medicines to address tomorrow's medical challenges. Apart from its products and services offered through Allergan Aesthetics, AbbVie also boasts impactful products in key areas such as immunology, oncology, neuroscience, eye care, virology, women's health, and gastroenterology.
Sirona Biochem's CEO, Howard Verrico, said clinical trials of TFC-1067 had found it to be safer and more effective at treating hyperpigmentation, dark spots, and melasma compared to any other ingredient on the market.
Dr. Linda Pullan of Pullan Consulting said the deal presents an enormous opportunity for both companies as it combines AbbVie's global presence and Sirona Biochem's disruptive technology. She added that Sirona Biochem stands to generate steady income from the deal on top of the milestone and upfront payments.
AbbVie and Sirona Biochem did not disclose other details of the deal as per their signed standard contractual terms. However, Sirona Biochem likely stands to gain substantial income from annual royalty payments once AbbVie is able to solidify its presence in the $8 billion global skin-lightening market.
Sirona's current pipeline includes cell preservation and repair treatments, keloid therapy, scar therapy, anti-aging, anti-wrinkle, and cellulite treatment. Sirona Biochem is also currently focused on developing a treatment for diabetic animals and a novel anti-viral treatment for humans. TFChem, Sirona's scientific development branch in France, has won several scientific accolades and European Union and French government grants.
For more information, please visit https://www.sironabiochem.com
or download their Investor's Presentation
The global exclusive licensing agreement includes up-front payments from AbbVie to Sirona Biochem. It also includes milestone payments and royalty payments for sales generated from commercial products using Sirona's patents. AbbVie and Sirona are expected to sign a separate definitive supply agreement, which will see the latter become a major supplier of the patented compounds.
AbbVie, through its subsidiary Allergan Aesthetics, controls a large portion of the global aesthetics market. The company, one of the top five pharmaceutical companies in the world based on revenue, plans to capitalize on Sirona Biochem's TFC-1067 compound, which is expected to replace hydroquinone as the next gold standard for creating an even skin tone.
The deal is part of Abbie's ongoing mission to discover and deliver new and innovative medicines to address tomorrow's medical challenges. Apart from its products and services offered through Allergan Aesthetics, AbbVie also boasts impactful products in key areas such as immunology, oncology, neuroscience, eye care, virology, women's health, and gastroenterology.
Sirona Biochem's CEO, Howard Verrico, said clinical trials of TFC-1067 had found it to be safer and more effective at treating hyperpigmentation, dark spots, and melasma compared to any other ingredient on the market.
Dr. Linda Pullan of Pullan Consulting said the deal presents an enormous opportunity for both companies as it combines AbbVie's global presence and Sirona Biochem's disruptive technology. She added that Sirona Biochem stands to generate steady income from the deal on top of the milestone and upfront payments.
AbbVie and Sirona Biochem did not disclose other details of the deal as per their signed standard contractual terms. However, Sirona Biochem likely stands to gain substantial income from annual royalty payments once AbbVie is able to solidify its presence in the $8 billion global skin-lightening market.
Sirona's current pipeline includes cell preservation and repair treatments, keloid therapy, scar therapy, anti-aging, anti-wrinkle, and cellulite treatment. Sirona Biochem is also currently focused on developing a treatment for diabetic animals and a novel anti-viral treatment for humans. TFChem, Sirona's scientific development branch in France, has won several scientific accolades and European Union and French government grants.
For more information, please visit https://www.sironabiochem.com
or download their Investor's Presentation
Source: Sirona Biochem Corp.
Filed Under: Medical
0 Comments
Latest on PrZen
- Launch of Def Leppard beauty collection creating Hysteria in the makeup industry
- Ismail Sirdah' Guide To Landing Event Sponsorships
- Children's Shoe Brand joins Soles4Souls in Ukrainian Refugee Relief Efforts
- The Data Economics Company announces partnership with Incradia to release the ReVerse franchise on Lydion-based Game Development Platform
- iTech offers 60-days free trial on expEDIum Medical Billing® product
- Completion of funding round brings Metaphysiks one step closer to embodying the Metaverse
- On Anniversary of Surfside Tragedy, New Book Coaches Residents to Identify Warning Signs
- CHASM unveils highly-respected CEO John Kawola as its first independent board member
- IOTech announces a major new release of Edge XRT, its software platform for time-critical OT systems
- Connect Fibre Partners With Linksys and Axiros
- Bacchus Wine & Spirits Jumps To Elite 'Top 20' Position In Beverage Dynamics Top 100 Retailers for 2022
- CPC Scientific Announces New California Peptide API Manufacturing Facility
- PermaTherm 2022 Family Fun Day
- New development in Ramsey called Williams Woods!
- Top New Jersey Engagement Shoot Locations and couples who totally nailed it
- BEC Technologies RidgeWave® 7000 Series Achieves AT&T Certification
- Calgary-based Orthodontics Provider Opens New Location
- Entrinsik Promotes Robin Lamb to Vice President of Client Services
- Announcing The Christina Hepburn Breast Cancer Support Campaign
- Altavoz Distribution Launches Regina Belle Records